Abstract
Efficacy of oral triple upfront combination therapy (long-acting prostacyclin analogue, endothelin receptor antagonist, phosphodiesterase 5 inhibitor) in the patients with idiopathic/heritable pulmonary arterial hypertension
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have